key: cord-1049750-24451vgo
authors: Huang, Chao; Yang, Lijun; Pan, Jia; Xu, Xiaomei; Peng, Rong
title: Correlation between vaccine coverage and the COVID‐19 pandemic throughout the world: Based on real‐world data
date: 2022-02-04
journal: J Med Virol
DOI: 10.1002/jmv.27609
sha: 6c9622175fc67615fb25a463f9cfc1217c2051ef
doc_id: 1049750
cord_uid: 24451vgo

The aim of the study was to examine the correlation between COVID‐19 vaccine coverage rates and outcomes of the COVID‐19 epidemic in the case of COVID‐19 variants based on real‐world data. The data came from Our World in Data, which is building the international COVID‐19 vaccination data set and is an open‐source data set for everyone to use. The vaccination data set uses the most recent official numbers from governments and health ministries worldwide. We assessed the correlation between COVID‐19 vaccine coverage rates and outcomes of the COVID‐19 epidemic with existing variants by performing temporal analysis and spatial analysis. Overall, new cases per million population, the reproduction rate of COVID‐19, new deaths from all causes per million population, excess mortality attributed to COVID‐19 pandemic, and hospital patients or intensive care unit (ICU) patients per million population were not decreased with the time course. However, at the same time point, new cases per million population, the reproduction rate of COVID‐19, new deaths per million population, and hospital patients or ICU patients per million population gradually decreased as the rate of vaccination coverage increased. High coverage percentages of COVID‐19 vaccination were negatively correlated with the reproduction rate of COVID‐19 (correlation coefficient −0.116) and ICU patients per million of the local population (correlation coefficient −0.055). Currently, there is no effective treatment for the COVID‐19 pandemic, and prevention of the COVID‐19 pandemic mainly depends on vaccines, especially when the rate of COVID‐19 vaccine coverage is over 60%. The benefits of preventing severe disease and preventing transmission of infection are likely to be obvious.

Current epidemiologic data indicate that COVID-19 appears to have the ability for sustained human-to-human transmission. 1 [4] [5] [6] [7] To date, there has been no effective drug to reduce the spread of COVID-19. Ideally, the COVID-19 vaccine would be the most effective way to prevent disease, prevent asymptomatic infection, and stop transmission. Global efforts to produce vaccines for COVID-19 have gained momentum. 8 Active or planned COVID-19 vaccine trials include more than 690 000 individuals across the globe, and this number will grow as further studies commence. 9 To ensure equitable global access to COVID-19 vaccines once these vaccines are available and to private donors and foundations to finance the manufacturing and distribution of vaccines for low-income and middle-income countries (LMICs), the COVID-19 Vaccines Global Access (COVAX) Facility provides participating countries an opportunity to secure early access to the vaccines. 10 However, vaccination across the world has progressed slowly in both high-income countries (HICs) and LMICs. 11 Both HICs and LMICs will likely encounter barriers and challenges to rolling out vaccines. Additionally, some worry that the emergence of COVID-19 variants may tip the scales in favor of infection enhancement. 2 In some regions, the proportion of citizens who seem inclined to receive the COVID-19 vaccine is probably too small to effectively stop the spread of the disease. 12 This situation requires fostering a climate of respectful mutual trust between science and society, where scientific knowledge is not only preached but also cultivated and sustained, thanks to the emphatic understanding of citizens' worries, needs of reassurance, and health expectations. Such evidence should be considered before more resources are allocated toward the deployment of these vaccines. Based on global data analysis, 13 we examined whether there is always a benefit to conducting a mass COVID-19 vaccination policy in reducing COVID-19 cases and fatalities and in preventing severe disease in the case of COVID-19 variants. We hope that our research can facilitate easy and quick decision-making for COVID-19 vaccination policies for global health administration.

The data come from Our World in Data, which is building the international COVID-19 vaccination data set and is an open-source data set for everyone to use. 13 The vaccination data set uses the most recent official numbers from governments and health ministries worldwide. In this article, six key indicators were used to detect the correlation between COVID-19 vaccine coverage rates and outcomes of the COVID-19 epi- This study examines the correlation between COVID-19 vaccine coverage rates and outcomes of the COVID-19 epidemic in the case of COVID-19 variants by performing a temporal analysis and spatial analysis. Plots and correlation analyses were constructed to visualize whether there is always a benefit to conducting a mass COVID-19 vaccination policy in reducing COVID-19 cases and fatalities, in preventing severe disease, in preventing transmission of infection, and against variants. R 3.6.3 and RStudio 1.2.5019 were used for data analysis in this study. The analysis code in RStudio is presented in Appendix file S1.

We have listed the COVID-19 epidemiology and vaccination rates on each continent from January 1, 2020, to August 20, 2021 (Table 1 ). Table 1 ). The low average coverage rate of the COVID-19

vaccine is probably too small to effectively stop the spread of the disease. We hope that our research can facilitate easy and quick Second, due to some confounding factors, the quantitative contribution of COVID-19 vaccine coverage to outcomes cannot be determined.

Based on the results of our temporal and spatial analysis of the correlation between the COVID-19 vaccine coverage rates and outcomes of the to publish, or preparation of the manuscript.

The author declares that there are no conflict of interests.

Not applicable.

Rong Peng conceptualized and designed the study. Rong Peng and Chao Huang put forward the outline of the article. Rong Peng, Lijun

Yang, Jia Pan made data analysis, draw pictures, and drafted the manuscript. Xiaomei Xu revised the article. All authors read and approved the final manuscript.

The data that support the findings of this study are openly available in [repository name "A global database of COVID-19 vaccinations"] at https://ourworldindata.org/covid-vaccinations, reference number. 13 ORCID Rong Peng http://orcid.org/0000-0001-5247-277X

Early transmission dynamics in Wuhan, China, of novel coronavirus-Infected pneumonia

Infection-enhancing anti-SARS-CoV-2 antibodies recognize both the original Wuhan/D614G strain and Delta variants. A potential risk for mass vaccination

COVID-19: unmasking emerging SARS-CoV-2 variants, vaccines and therapeutic strategies

Potential for global spread of a novel coronavirus from China

COVID-19 human challenge studies: ethical issues

Historical evidence for economic effects of COVID-19

Prioritising COVID-19 vaccination in changing social and epidemiological landscapes: a mathematical modelling study

Reserving coronavirus disease 2019 vaccines for global access: cross sectional analysis

An interactive website tracking COVID-19 vaccine development

Who should be prioritised for COVID-19 vaccination?

Vaccinate fast but leave no one behind: a call to action for COVID-19 vaccination in Spain

Mistrust in biomedical research and vaccine hesitancy: the forefront challenge in the battle against COVID-19 in Italy

A global database of COVID-19 vaccinations

Acceptance of COVID-19 vaccination and correlated variables among global populations: a systematic review and meta-analysis